KR102537948B1 - Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof - Google Patents
Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof Download PDFInfo
- Publication number
- KR102537948B1 KR102537948B1 KR1020220069647A KR20220069647A KR102537948B1 KR 102537948 B1 KR102537948 B1 KR 102537948B1 KR 1020220069647 A KR1020220069647 A KR 1020220069647A KR 20220069647 A KR20220069647 A KR 20220069647A KR 102537948 B1 KR102537948 B1 KR 102537948B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- distillate
- composition
- hot water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 32
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000006872 improvement Effects 0.000 title description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- 239000000284 extract Substances 0.000 claims description 47
- 229940037003 alum Drugs 0.000 claims description 26
- 241000208340 Araliaceae Species 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000000498 cooling water Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- WIONIXOBNMDJFJ-UHFFFAOYSA-N dictamnine Natural products C1=CC=C2C(OC)=C(C=CO3)C3=NC2=C1 WIONIXOBNMDJFJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 3
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 3
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 claims description 3
- KDKJYYNXYAZPIK-UHFFFAOYSA-J aluminum potassium disulfate hydrate Chemical compound O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KDKJYYNXYAZPIK-UHFFFAOYSA-J 0.000 claims description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 3
- 235000012734 epicatechin Nutrition 0.000 claims description 3
- 229940043357 mangiferin Drugs 0.000 claims description 3
- 241001412149 Eriogonum fasciculatum Species 0.000 claims description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 2
- 229930014456 matrine Natural products 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 241000219051 Fagopyrum Species 0.000 claims 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 abstract description 24
- 210000002510 keratinocyte Anatomy 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 24
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000006210 lotion Substances 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 241000411851 herbal medicine Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 206010003645 Atopy Diseases 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 229940096397 interleukin-8 Drugs 0.000 description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000002474 Tinea Diseases 0.000 description 5
- 241000893966 Trichophyton verrucosum Species 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 241000272171 Scolopacidae Species 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008361 herbal raw material Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000123855 Dictamnus dasycarpus Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- NLSTZAFFNDSJGQ-UHFFFAOYSA-N Matrin Natural products O=C1CCCN2CC3CCNC4CCCC(C34)C12 NLSTZAFFNDSJGQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 241001079007 Phellodendron chinense Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 244000261559 Smilax china Species 0.000 description 1
- 235000000485 Smilax china Nutrition 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 231100001067 mild skin irritation Toxicity 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 201000011414 pompholyx Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021148 salty food Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 천연 복합성분을 함유하는 중증 피부질환의 개선 또는 치료용 조성물 및 그 제조 방법에 관한 것으로서, 구체적으로는 천연 복합성분을 함유하여 항염 및 항산화 활성이 강력하고, 각질형성세포에 대한 독성이 없어 아토피 피부염과 같은 중증 피부질환의 개선 또는 치료에 사용하기 적합한 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a composition for improving or treating severe skin diseases containing natural complex components and a method for preparing the same, and specifically, contains natural complex components and has strong anti-inflammatory and antioxidant activities, and has no toxicity to keratinocytes. It relates to a composition suitable for use in improving or treating severe skin diseases such as atopic dermatitis and a method for preparing the same.
아토피 피부염, 건선, 루푸스 등과 같은 중증 피부질환은 난치성 질환으로서 치료나 개선이 쉽지 않으며, 특히 현대사회에서 서구화된 식습관, 환경오염 등이 심해짐에 따라 환자 수가 증가하고 있는 질환이다.Severe skin diseases such as atopic dermatitis, psoriasis, and lupus are intractable diseases that are not easy to treat or improve. In particular, the number of patients is increasing as westernized eating habits and environmental pollution become severe in modern society.
특히 '아토피(atopy)'는 1925년 코카(Coca)라는 학자가 처음으로 사용한 용어로, 음식물이나 기타 흡입성 물질에 대한 선천성 알러지(allergy) 반응을 의미한다. 'atopy'는 그리스어로 '알 수 없는', '괴상한'이라는 뜻으로 그 의미에서도 알 수 있듯 정확한 원인은 알 수 없고, 치료가 힘든 난치성 질환이다. 아토피성 피부염(atopic dermatitis)은 보통 습진(eczema), 고초열(hayfever), 천식(asthma), 알레르기(allergy) 등을 잘 일으키는 유전적 경향을 보이는 체질을 가진 사람에게서 많이 발생되는 만성 피부염으로 흔히 태열이라 부르고 유아 습진으로 시작, 만성, 재발성 경과를 보인다.In particular, 'atopy' is a term first used by a scholar named Coca in 1925, and refers to a congenital allergic reaction to food or other inhalable substances. 'atopy' means 'unknown' or 'strange' in Greek. Atopic dermatitis is a chronic dermatitis that commonly occurs in people with a genetic tendency to cause eczema, hayfever, asthma, and allergy. It is called fetal fever and begins with infantile eczema and shows a chronic, recurrent course.
아토피의 발생 원인은 아직까지 확실히 밝혀져 있지 않다. 다만 유전적, 면역학적 요인이 깊숙이 관계되리라 생각되며 동시에 환경적, 사회적, 정신적 요인 등 다양한 주변인자들도 연관이 있으리라고 생각되고 있다.The cause of atopy has not yet been clearly identified. However, it is thought that genetic and immunological factors are deeply related, and at the same time, various peripheral factors such as environmental, social, and mental factors are also thought to be related.
오늘날 일반적인 아토피성 피부염의 치료는 소양감의 조절, 2차 병변 발생의 방지를 목적으로 하고, 약물투여 방법에 따라 외용 방법, 내복 방법, 그리고 면역 방법 등이 사용되고 있다. 외용 방법으로는 피부를 세정하는 방법, 스테로이드 계열의 연고제를 바르는 방법, 그리고 보습제를 바르는 방법 등이 사용되고 있다. 특히 스테로이드는 일종의 부신피질 호르몬제로서 효과는 매우 빠르지만, 장기간 사용했을 때 피부의 위축이나 소아 환자에서 성장지연의 가능성 등 각종 부작용이 문제되고 있다. 보습제는 건조한 피부에 수분을 공급 및 유지하기 위한 화장품류를 바르는 것을 말한다. 내복 방법으로 주로 사용하는 아토피 치료약은 항히스타민제, 스테로이드계 의약품이 주로 사용되고 있다. 면역 방법은 신체의 면역력을 자연적으로 길러줄 수 있도록 주변 환경을 조정하거나 유도하는 것이다Treatment of atopic dermatitis in general today aims at control of pruritus and prevention of secondary lesions, and depending on drug administration methods, external methods, internal methods, and immune methods are used. As an external method, a method of washing the skin, a method of applying a steroid-based ointment, and a method of applying a moisturizer are used. In particular, steroids are a kind of adrenal cortical hormone drug, and the effect is very fast, but when used for a long time, various side effects such as skin atrophy or growth retardation in pediatric patients are problematic. Moisturizer refers to applying cosmetics for supplying and maintaining moisture to dry skin. Antihistamines and steroid-based medicines are mainly used as atopy treatment drugs that are mainly used internally. Immune method is to adjust or induce the surrounding environment to naturally develop the body's immunity.
일반의약품 조성물은 종래의 개발된 생약추출물 또는 생약제제를 함유하여 아토피성질환 및 기타 피부질환(건선, 습진) 등의 치료를 하는데, 스테로이드 및 항히스타민 성분으로 인한 피부 침착, 착색 및 심한 가려움증 등의 부작용을 유발하며, 사용을 중지할 시 확장성 질환에 대한 심각한 부작용과 3차 세균 감염으로 발전될 수 있다.Over-the-counter pharmaceutical compositions contain conventionally developed herbal extracts or herbal preparations to treat atopic diseases and other skin diseases (psoriasis, eczema), and side effects such as skin deposition, pigmentation and severe itching due to steroids and antihistamine When use is discontinued, it can develop into serious side effects for expansive disease and tertiary bacterial infection.
소아와 성인기의 면역 체계의 특성이 아토피의 발생 및 병리적 특성과 연관될 수 있다. 우리나라 신생아의 70-80%가 태열을 경험한다. 이들 중의 대부분은 자연스럽게 소아기에 접어들면서 치료되는 경향을 보인다. 그러나 일부 보고에 의하면 이들 중의 20-30%는 소아 아토피로 진행이 된다고 한다. 이러한 현상은 면역계의 자연스러운 변화인데, 즉 유아기의 특이면역이 소아기에 접어들면서 자연면역이 회복이 되면서 아토피는 치유가 되는 것이다. The characteristics of the immune system in childhood and adulthood may be related to the development and pathology of atopy. 70-80% of Korean newborns experience fetal fever. Most of these tend to be treated naturally as they enter childhood. However, according to some reports, 20-30% of them progress to childhood atopy. This phenomenon is a natural change of the immune system, that is, as the specific immunity of infancy enters childhood and the natural immunity recovers, atopy is healed.
그래서 이 시기의 면역학적인 특징은 자연면역이 활발하게 성장을 하는 시기라고 볼 수 있다. 즉, 아이들이 감기와 같은 발열증상들을 경험하면서 자연 면역계가 성장하는 과정인 것이다. 그러므로 아이들이 감기나 발열증상이 있을 때 해열제나 항생제를 오·남용하는 것은 바람직한 것이 아니다. 성인의 경우, 이 시기는 자연 면역계와 특이 면역 모두 어느 정도는 성숙되어 있는 시기다. 즉, 건강하든 건강하지 않든 면역계는 어느 정도 고착화되어 있는 것이다.So, the immunological characteristics of this period can be seen as a period of active growth of natural immunity. In other words, it is a process in which the natural immune system grows as children experience fever symptoms such as a cold. Therefore, it is not desirable for children to misuse or abuse antipyretics or antibiotics when they have cold or fever symptoms. In adults, this is a time when both the innate and specific immune systems are maturing to some extent. In other words, whether healthy or unhealthy, the immune system is fixed to some extent.
양의학과 한의학에서는 아토피 피부염이 생기는 원인에 대해 '몸 안에 뭉친 열이 독을 만들었기 때문'이라고 보고 있다. 몸속 깊숙이 숨어 있던 열독이 피부층까지 올라와 각종 트러블을 일으키는 것이다. 따라서 열독이 풀리지 않는 한 아토피 피부염은 계속 재발할 수밖에 없다. 특히 임신 중에 맵고 짠 음식이나 과도한 카페인, 알코올, 인스턴트, 기름진 음식 등을 많이 섭취했거나, 자궁 안에 노폐물이 많이 쌓였거나, 자궁이 약한 경우 태내에 열이 쌓여 태아에게 아토피 피부염을 유발한다고 보고 있다. 열독은 피부 이상만을 일으키는 것이 아니라 몸의 면역력을 떨어뜨려 각종 합병증을 유발시키므로 단순히 증상만 치료하는 것이 아니라 아토피 피부염의 원인을 찾아 근본적인 치료를 해야 한다고 주장한다. 즉, 아토피 피부염의 원인이 되는 열독을 풀어 주고, 알레르기에 대항할 수 있는 자생력을 키우는 등 근본치료를 해야 재발을 막을 수 있다고 이야기하고 있다.Western medicine and oriental medicine view the cause of atopic dermatitis as 'because heat accumulated in the body created poison'. Heat poison hidden deep inside the body rises to the skin layer and causes various troubles. Therefore, atopic dermatitis will inevitably recur unless the overheating is resolved. In particular, if you consumed a lot of spicy and salty food, excessive caffeine, alcohol, instant, greasy food, etc. during pregnancy, or if a lot of waste was accumulated in the uterus, or if the uterus was weak, it is believed that heat builds up in the womb and causes atopic dermatitis in the fetus. Heat poisoning not only causes skin abnormalities, but also lowers the body's immunity and causes various complications, so it is argued that it is necessary to find the cause of atopic dermatitis and treat it fundamentally, rather than simply treating symptoms. In other words, it is said that the recurrence can be prevented only by fundamental treatment, such as releasing the fever poison that causes atopic dermatitis and developing self-sustaining power to fight allergies.
염증세포들은 주로 대식세포, 호산구와 같은 속발반응에 관여하는 세포들이며 이들은 아토피성 피부염의 급성기에 존재하던 세포들에서 생성된 IL-1 과 TNF-α과 같은 사이토카인(cytokine)의 직접적인 영향으로 피부에 침투한 것으로 여겨지고 있다. 이 질환은 TH1/TH2 면역 반응과 큰 연관이 있다. 항원이 제시되면 원시 T 세포(naive T cell)은 인터루킨(interleukin, IL)-12, IL-18, 또는 IL-4에 노출되어 TH1이나 TH2 세포로 분화된다. TH1 세포는 염증성 사이토카인인 인터페론 감마(interferon-gamma, IFN-γ)와 종양괴사인자(tumor necrosis factor-alpha, TNF-α)를 분비하며 TH2를 억제하는 반면, TH2 세포는 IL-4, IL-5, IL-13 등을 분비하며 TH1 반응을 억제한다. 특히, IL-8은 주로 염증과 연관이 되는 사이토카인인데, 산화적 스트레스에 의해 증가되는 것으로 알려진 IL-8은 국소적 염증에 중요한 매개 변수가 된다. Inflammatory cells are mainly macrophages and eosinophils, which are involved in secondary reactions, and they are directly affected by cytokines such as IL-1 and TNF-α produced by cells that existed in the acute phase of atopic dermatitis. is believed to have infiltrated This disease is strongly related to the TH1/TH2 immune response. When an antigen is presented, naive T cells are exposed to interleukin (IL)-12, IL-18, or IL-4 and differentiate into TH1 or TH2 cells. TH1 cells secrete inflammatory cytokines interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) and suppress TH2, while TH2 cells secrete IL-4 and IL-4. It secretes -5 and IL-13 and suppresses the TH1 response. In particular, IL-8 is a cytokine mainly associated with inflammation, and IL-8, which is known to be increased by oxidative stress, is an important parameter for local inflammation.
최근 아토피성 피부염과 같은 중증 피부질환에 관한 식물, 광물, 동물성의 천연물 소재 연구가 활발히 진행되고 있는 현황이다. 그러나 아직까지 아토피 피부염에 뛰어난 효능을 보이는 동시에 부작용이 없고 사용이 용이한 의약 조성물이나, 화장품 조성물 또는 식품조성물 등은 없는 실정이다. Recently, studies on natural materials of plants, minerals, and animals related to severe skin diseases such as atopic dermatitis are being actively conducted. However, there is still no pharmaceutical composition, cosmetic composition, or food composition that shows excellent efficacy for atopic dermatitis and has no side effects and is easy to use.
본 연구팀은 다양한 약재와 천연 소재들을 연구하고 실험하여 백반 등의 생약이 아토피성 피부질환의 개선 또는 치료에 효능이 있음을 발견하였으며, 또한 이를 열수 추출 시 일정 온도 이상에서 휘발되는 증류성분을 냉각 회수하면 정유성분, 방향족성분 및 항산화성분이 풍부한 열수 증류 분획을 확보할 수 있다는 것을 발견하여, 아토피 피부염과 같은 중증 피부질환의 개선 또는 치료에 가장 좋은 효능을 나타내는 조성물을 배합함으로써 본 발명을 완성하였다.The research team researched and experimented with various medicinal materials and natural materials and found that herbal medicines such as alum are effective in improving or treating atopic skin diseases. Also, when extracting hot water, distilled components that volatilize at a certain temperature or higher are recovered by cooling. The present invention was completed by combining a composition exhibiting the best efficacy for improving or treating severe skin diseases such as atopic dermatitis.
이에, 본 발명이 해결하고자 하는 과제는 천연 복합성분을 함유하여 항염 및 항산화 활성이 우수하고 부작용이 없어 아토피 피부염과 같은 중증 피부질환의 개선 또는 치료에 유용한 조성물을 제공하는 것이다.Therefore, the problem to be solved by the present invention is to provide a composition useful for improving or treating severe skin diseases such as atopic dermatitis because it contains natural complex components, has excellent anti-inflammatory and antioxidant activities, and has no side effects.
본 발명이 해결하고자 하는 다른 과제는 위와 같은 위와 같은 중증 피부질환의 개선 또는 치료용 조성물을 제조하는 방법을 제공하는 것이다. Another problem to be solved by the present invention is to provide a method for preparing a composition for improving or treating severe skin diseases such as the above.
본 발명의 과제들은 이상에서 언급한 기술적 과제로 제한되지 않으며, 언급되지 않은 또 다른 기술적 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The tasks of the present invention are not limited to the technical tasks mentioned above, and other technical tasks not mentioned will be clearly understood by those skilled in the art from the following description.
상기 과제를 해결하기 위한 본 발명의 일 실시예에 따른 중증 피부질환의 개선 또는 치료용 조성물은 백반 2-8 중량부, 백선피 2-8 중량부, 고삼 2-8 중량부 및 토복령 2-8 중량부를 포함하는 혼합물의 열수 추출물의 증류액을 포함한다.The composition for improving or treating severe skin diseases according to an embodiment of the present invention for solving the above problems is 2-8 parts by weight of alum, 2-8 parts by weight of white ginseng skin, 2-8 parts by weight of Gosam, and 2-8 parts by weight of Tobokryeong. 8 parts by weight of the distillate of the hot water extract of the mixture.
또한, 상기 혼합물은 황백 2-8 중량부를 더 포함할 수 있다.In addition, the mixture may further include 2-8 parts by weight of yellowish white.
또한, 상기 혼합물은 백반 3-7 중량부, 백선피 3-7 중량부, 고삼 3-7 중량부 및 토복령 3-7 중량부를 포함할 수 있고, 황백 3-7 중량부를 더 포함할 수 있다.In addition, the mixture may include 3-7 parts by weight of alum, 3-7 parts by weight of baekseonpi, 3-7 parts by weight of high ginseng, and 3-7 parts by weight of Tobokryeong, and may further include 3-7 parts by weight of yellow buckwheat. .
상기 중증 피부질환은 염증성 피부질환, (자가)면역성 피부질환 또는 염증을 동반한 면역성 피부질환일 수 있다. 구체적인 실시예에서, 이러한 피부질환은 아토피 피부염(atopic dermatitis), 건선(psoriasis), 루푸스(systemic lupus erythematosus), 지루성 피부염(seborrheic dermatitis), 습진(eczema) 및 한포진(pompholyx)으로 이루어진 군에서 선택되는 하나 이상을 포함할 수 있다. 예시적인 실시예에서, 상기 중증 피부질환은 아토피 피부염일 수 있다. 다만 본 발명의 실시예가 이에 제한되는 것은 아니다.The severe skin disease may be an inflammatory skin disease, an (auto)immune skin disease, or an immune skin disease accompanied by inflammation. In a specific embodiment, the skin disease is selected from the group consisting of atopic dermatitis, psoriasis, systemic lupus erythematosus, seborrheic dermatitis, eczema and pompholyx may include one or more. In an exemplary embodiment, the severe skin disease may be atopic dermatitis. However, embodiments of the present invention are not limited thereto.
상기 약재들의 학명 또는 상기 약재들의 기원식물의 학명은 하기와 같을 수 있으나, 이에 제한되는 것은 아니다.The scientific names of the medicines or the scientific names of the plants of origin of the medicines may be as follows, but are not limited thereto.
- 백반(白礬): Alumen- White spots: Alumen
- 백선피(白鮮皮): Dictamnus dasycarpus Turcz.- Ringworm: Dictamnus dasycarpus Turcz.
- 고삼(苦參): Sophora flavescens Aiton - Kosam (苦參): Sophora flavescens Aiton
- 토복령(土茯): Smilax glabra, Smilax china - Tobokryung (土茯): Smilax glabra, Smilax china
- 황백(黃柏): Phellodendron amurense Ruprecht, Phellodendron chinense Schneider- Yellow and white: Phellodendron amurense Ruprecht, Phellodendron chinense Schneider
상기 백반은 황산알루미늄칼륨수화물(KAl(SO4)2·12H2O)을 포함하는 것일 수 있고, 상기 백선피는 딕탐닌(dictamnine)을 포함하는 것일 수 있고, 상기 고삼은 마트린(matrine)을 포함하는 것일 수 있고, 상기 황백은 망기페린(mangiferin)을 포함하는 것일 수 있고, 상기 토복령은 에피카테킨(epicatechin)을 포함하는 것일 수 있다. 다만 본 발명의 실시예가 이에 제한되는 것은 아니다.The alum may contain aluminum sulfate potassium hydrate (KAl(SO 4 ) 2 12H 2 O), the alum may contain dictamnine, and the gosam may contain matrine. The yellowish white may include mangiferin, and the earthy tobokryeong may include epicatechin. However, embodiments of the present invention are not limited thereto.
이에 따라, 본 발명의 조성물은 황산알루미늄칼륨수화물, 딕탐닌, 마트린, 망기페린 및 에피카테킨으로 이루어진 군에서 선택되는 하나 이상의 지표성분을 포함할 수 있다.Accordingly, the composition of the present invention may include at least one indicator component selected from the group consisting of aluminum sulfate potassium hydrate, dictamnin, matrin, mangiferin, and epicatechin.
상기 과제를 해결하기 위한 본 발명의 다른 실시예에 따른 중증 피부질환의 개선 또는 치료용 조성물은 백반 열수 추출물의 증류액 2-8 중량부, 백선피 열수 추출물의 증류액 2-8 중량부, 고삼 열수 추출물의 증류액 2-8 중량부 및 토복령 열수 추출물의 증류액 2-8 중량부를 포함한다. A composition for improving or treating severe skin diseases according to another embodiment of the present invention for solving the above problems is 2-8 parts by weight of a distillate of hot water extract of alum, 2-8 parts by weight of a distillate of hot water extract of white pisces, 2-8 parts by weight of the distillate of the hot water extract and 2-8 parts by weight of the distillate of the hot water extract of Tobokryeong.
또한, 황백 열수 추출물의 증류액 2-8 중량부를 더 포함할 수 있다.In addition, 2-8 parts by weight of the distillate of the yellow-white hot water extract may be further included.
또한, 상기 조성물은 백반 열수 추출물의 증류액 3-7 중량부, 백선피 열수 추출물의 증류액 3-7 중량부, 고삼 열수 추출물의 증류액 3-7 중량부 및 토복령 열수 추출물의 증류액 3-7 중량부를 포함할 수 있고, 황백 열수 추출물의 증류액 3-7 중량부를 더 포함할 수 있다.In addition, the composition contains 3-7 parts by weight of a distillate of alum hot water extract, 3-7 parts by weight of a distillate of a hot water extract of Baekseonpi, 3-7 parts by weight of a distillate of a hot water extract of Gosam, and 3 parts by weight of a distillate of a hot water extract of Tobokryeong. -7 parts by weight, and may further include 3-7 parts by weight of a distillate of yellow-white hot water extract.
상기 다른 과제를 해결하기 위한 본 발명의 일 실시예에 따른 중증 피부질환의 개선 또는 치료용 조성물의 제조 방법은 (a) 백반 2-8 중량부, 백선피 2-8 중량부, 고삼 2-8 중량부 및 토복령 2-8 중량부를 포함하는 혼합물을 80-100 ℃로 8-48시간 동안 가열하고 여과하여 열수 추출물을 얻는 단계; (b) 상기 열수 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계; 및 (c) 상기 액화된 것을 원심분리하여 고형분을 제거하고 상등액을 취하여 증류액을 수득하는 단계를 포함한다. A method for preparing a composition for improving or treating severe skin diseases according to an embodiment of the present invention to solve the above other problems is (a) 2-8 parts by weight of alum, 2-8 parts by weight of ringworm skin, 2-8 parts by weight of gosam obtaining a hot water extract by heating and filtering a mixture containing 2-8 parts by weight and 2-8 parts by weight at 80-100 ° C for 8-48 hours; (b) liquefying the steam generated by heating the hot water extract at 90-100 °C with a cooling water pipe at 4-10 °C; and (c) centrifuging the liquefied liquid to remove solids and taking the supernatant to obtain a distillate.
상기 원심분리는 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 수행하는 것일 수 있다.The centrifugation may be performed at 8,000-14,000 rpm and 2-8 °C for 10-50 minutes.
또한, 상기 혼합물은 황백 2-8 중량부를 더 포함할 수 있다.In addition, the mixture may further include 2-8 parts by weight of yellowish white.
상기 제조 방법은 (d) 상기 가열 후 잔류한 추출물 10-30 중량부를 상기 증류액 70-90 중량부에 혼합하는 단계를 더 포함할 수 있다.The manufacturing method may further include (d) mixing 10-30 parts by weight of the extract remaining after the heating with 70-90 parts by weight of the distillate.
상기 다른 과제를 해결하기 위한 본 발명의 다른 실시예에 따른 중증 피부질환의 개선 또는 치료용 조성물의 제조 방법은 (a) 백반, 백선피, 고삼, 토복령 및 황백을 각각 80-100 ℃로 8-48시간 동안 가열하고 여과하여 각각의 열수 추출물을 얻는 단계; (b) 상기 각 열수 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계; (c) 상기 액화된 것을 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 원심분리하여 고형분을 제거하고 상등액을 취하여 각각의 증류액을 수득하는 단계; 및 (d) 상기 백반의 증류액 2-8 중량부, 백선피의 증류액 2-8 중량부, 고삼의 증류액 2-8 중량부, 토복령의 증류액 2-8 중량부 및 황백의 증류액 2-8 중량부를 서로 혼합하는 단계를 포함한다.A method for preparing a composition for improving or treating severe skin diseases according to another embodiment of the present invention for solving the above other problems is (a) alum, ringworm skin, gosam, tobokryeong, and yellow white, respectively, at 80-100 ℃ 8 - Heating for 48 hours and filtering to obtain each hot water extract; (b) liquefying the steam generated by heating each of the hot water extracts at 90-100 ° C with a cooling water pipe at 4-10 ° C; (c) centrifuging the liquefied product at 8,000-14,000 rpm and 2-8 ° C. for 10-50 minutes to remove the solid content and taking the supernatant to obtain each distillate; And (d) 2-8 parts by weight of the distillate of alum, 2-8 parts by weight of distillate of baekseonpi, 2-8 parts by weight of distillate of high ginseng, 2-8 parts by weight of distillate of tobokryeong, and yellowish white distillate 2-8 parts by weight are mixed with each other.
상기 실시예들에 따른 중증 피부질환의 개선 또는 치료용 조성물의 제조 방법은 수득한 증류액을 한외 여과막 또는 크로마토그래피를 이용하여 추가적으로 정제하는 단계를 더 포함할 수 있다.The method for preparing the composition for improving or treating severe skin diseases according to the above embodiments may further include further purifying the obtained distillate using an ultrafiltration membrane or chromatography.
한편, 상술한 증류액 또는 상등액의 밀도는 약 1 kg/L, 즉 정제수의 밀도와 근사하거나 실질적으로 동일할 수 있다. 따라서, 상술한 증류액 또는 상등액의 함량 단위인 '중량부(parts by weight)'는 '부피부(parts by volume)'와 실질적으로 동일한 단위일 수 있다.Meanwhile, the density of the above-mentioned distillate or supernatant may be about 1 kg/L, that is, close to or substantially equal to the density of purified water. Accordingly, 'parts by weight', which is a unit of content of the above-mentioned distillate or supernatant, may be substantially the same unit as 'parts by volume'.
본 발명의 조성물에 포함되는 추출물은 전술된 방법에 따라 추출되는 열수 추출물일 수 있으나 이에 제한되는 것은 아니며, 가온 추출, 액상 추출, 농축 액상 추출, 동결건조 및 분무건조로 이루어진 군에서 선택되는 하나 이상의 방법으로 추출 또는 제조되는 것일 수도 있다. 예를 들어 가온 추출의 경우, 생약재 원료들을 정제수로 세척한 후 혼합하고 C1-6의 알코올을 이용하여 1-5시간 동안 50-80 ℃로 가온하여 추출할 수 있다.The extract included in the composition of the present invention may be a hot water extract extracted according to the above-described method, but is not limited thereto, and at least one selected from the group consisting of warming extraction, liquid extraction, concentrated liquid extraction, lyophilization and spray drying It may be extracted or prepared by a method. For example, in the case of extraction by heating, herbal medicine raw materials are washed with purified water, mixed, and extracted by heating at 50-80 ° C. for 1-5 hours using C 1-6 alcohol.
본 발명의 다른 실시예에 따른 상기 조성물 또는 상기 제조 방법의 혼합물은 백반 2-8 중량부, 백선피 2-8 중량부, 고삼 2-8 중량부 및 황백 2-8 중량부를 포함하는 혼합물의 열수 추출물의 증류액을 포함한다. 또한, 상기 혼합물은 백반 3-7 중량부, 백선피 3-7 중량부, 고삼 3-7 중량부 및 황백 3-7 중량부를 포함할 수 있다.The mixture of the composition or the preparation method according to another embodiment of the present invention is hot water of a mixture comprising 2-8 parts by weight of alum, 2-8 parts by weight of white ginseng skin, 2-8 parts by weight of high ginseng, and 2-8 parts by weight of yellow white. Contains distillates of extracts. In addition, the mixture may include 3-7 parts by weight of alum, 3-7 parts by weight of baekseonpi, 3-7 parts by weight of high ginseng, and 3-7 parts by weight of yellow white.
본 발명의 다른 실시예에 따른 상기 조성물 또는 상기 제조 방법의 혼합물은 백반 열수 추출물의 증류액 2-8 중량부, 백선피 열수 추출물의 증류액 2-8 중량부, 고삼 열수 추출물의 증류액 2-8 중량부 및 황백 열수 추출물의 증류액 2-8 중량부를 포함한다. 또한, 상기 조성물은 백반 열수 추출물의 증류액 3-7 중량부, 백선피 열수 추출물의 증류액 3-7 중량부, 고삼 열수 추출물의 증류액 3-7 중량부 및 황백 열수 추출물의 증류액 3-7 중량부를 포함할 수 있다.The mixture of the composition or the preparation method according to another embodiment of the present invention comprises 2-8 parts by weight of a distillate of alum hot-water extract, 2-8 parts by weight of a distillate of a hot-water extract of white sandpiper, and 2-8 parts by weight of a distillate of a hot-water extract of Gosam. 8 parts by weight and 2-8 parts by weight of a distillate of yellow-white hot water extract. In addition, the composition comprises 3-7 parts by weight of a distillate of alum hot water extract, 3-7 parts by weight of a distillate of a hot water extract of Baekseonpi, 3-7 parts by weight of a distillate of a hot water extract of Gosam, and 3-7 parts by weight of a distillate of a yellow and white hot water extract. 7 parts by weight.
기타 실시예의 구체적인 사항들은 상세한 설명에 포함되어 있다.Other embodiment specifics are included in the detailed description.
본 발명의 실시예들에 따른 조성물은 천연 복합성분을 함유하여 항염 및 항산화 활성이 강력하고, 각질형성세포(keratinocyte)에 대한 독성이 없으며, 여러 성분들이 최적으로 배합됨에 따라 단일 성분 대비 상승작용 효과(synergistic effect)를 나타내기 때문에, 아토피 피부염과 같은 중증 피부질환의 개선 또는 치료에 사용하기 적합하다.Compositions according to embodiments of the present invention contain natural complex components, have strong anti-inflammatory and antioxidant activities, are non-toxic to keratinocytes, and have a synergistic effect compared to single components as several components are optimally combined. Since it exhibits a synergistic effect, it is suitable for use in improving or treating severe skin diseases such as atopic dermatitis.
본 발명의 실시예들에 따른 효과는 이상에서 예시된 내용에 의해 제한되지 않으며, 더욱 다양한 효과들이 본 명세서 내에 포함되어 있다.Effects according to the embodiments of the present invention are not limited by the contents exemplified above, and more diverse effects are included in the present specification.
도 1은 본 발명의 일 실험예에 따라 본 발명의 조성물의 각질형성세포(keratinocyte cell)에 대한 독성을 측정한 그래프이다.1 is a graph measuring the toxicity of the composition of the present invention to keratinocyte cells according to an experimental example of the present invention.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 실시예들은 본 발명의 개시가 완전하도록 하며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention, and how to achieve them, will become clear with reference to the detailed description of the following embodiments. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, and only the embodiments make the disclosure of the present invention complete, and those skilled in the art in the art to which the present invention belongs It is provided to fully inform the person of the scope of the invention, and the invention is only defined by the scope of the claims.
본 명세서에서 사용된 용어는 실시예들을 설명하기 위한 것이며 본 발명을 제한하고자 하는 것은 아니다. 본 명세서에서, '및/또는'은 언급된 아이템들의 각각 및 하나 이상의 모든 조합을 포함한다. 또, 단수형은 문구에서 특별히 언급하지 않는 한 복수형도 포함한다. 명세서에서 사용되는 '포함한다(comprises)' 및/또는 '포함하는(comprising)'은 언급된 구성요소 외에 하나 이상의 다른 구성요소의 존재 또는 추가를 배제하지 않는다. '-' 또는 '내지'를 사용하여 나타낸 수치 범위는 다른 언급이 없는 한 그 앞과 뒤에 기재된 값을 각각 하한과 상한으로서 포함하는 수치 범위를 나타낸다. '약' 또는 '대략'은 그 뒤에 기재된 값 또는 수치 범위의 20% 이내의 값 또는 수치 범위를 의미한다.Terminology used herein is for describing the embodiments and is not intended to limit the present invention. In this specification, 'and/or' includes each and every combination of one or more of the recited items. In addition, singular forms also include plural forms unless otherwise specified in the text. The terms 'comprises' and/or 'comprising' used in the specification do not exclude the presence or addition of one or more other elements other than the mentioned elements. Numerical ranges expressed using '-' or 'to' represent numerical ranges including the values listed before and after them as lower and upper limits, respectively, unless otherwise specified. 'About' or 'approximately' means a value or range of values within 20% of the value or range of values set forth thereafter.
또한, 본 발명의 실시예의 구성 요소를 설명하는 데 있어서, 제1, 제2, A, B, (a), (b) 등의 용어를 사용할 수 있다. 이러한 용어는 그 구성 요소를 다른 구성 요소와 구별하기 위한 것일 뿐, 그 용어에 의해 해당 구성 요소의 본질이나 차례 또는 순서 등이 한정되지 않는다.Also, terms such as first, second, A, B, (a), and (b) may be used to describe components of an embodiment of the present invention. These terms are only used to distinguish the component from other components, and the nature, order, or order of the corresponding component is not limited by the term.
다른 정의가 없다면, 본 명세서에서 사용되는 모든 용어(기술 및 과학적 용어를 포함)는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 공통적으로 이해될 수 있는 의미로 사용될 수 있을 것이다. 또 일반적으로 사용되는 사전에 정의되어 있는 용어들은 명백하게 특별히 정의되어 있지 않는 한 이상적으로 또는 과도하게 해석되지 않는다.Unless otherwise defined, all terms (including technical and scientific terms) used in this specification may be used in a meaning commonly understood by those of ordinary skill in the art to which the present invention belongs. In addition, terms defined in commonly used dictionaries are not interpreted ideally or excessively unless explicitly specifically defined.
그리고 본 발명의 실시예를 설명함에 있어, 관련된 공지 구성 또는 기능에 대한 구체적인 설명이 본 발명의 실시예에 대한 이해를 방해한다고 판단되는 경우에는 그 상세한 설명은 생략한다.And, in describing the embodiments of the present invention, if it is determined that a detailed description of a related known configuration or function hinders understanding of the embodiments of the present invention, the detailed description will be omitted.
본 명세서에서, '예방'이란 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸릴 수 있는 개체에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. As used herein, 'prevention' means suppressing the occurrence of a disease or disease in a subject who has never been diagnosed with the disease or disease, but is susceptible to such disease or disease.
본 명세서에서, '치료' 또는 '개선'이란 개체에서 (a) 질환 또는 질병의 발전(악화)의 억제, (b) 질환 또는 질병의 경감, 또는 (c) 질환 또는 질환의 제거를 의미한다. As used herein, 'treatment' or 'improvement' refers to (a) inhibition of development (exacerbation) of a disease or disease, (b) alleviation of a disease or disease, or (c) elimination of a disease or disease in a subject.
본 명세서에서, '개체'란 본 발명의 조성물을 투여하여 증상이 호전될 수 있는 질환을 가진 인간을 포함한 포유동물을 의미한다.In the present specification, 'subject' refers to mammals, including humans, having a disease whose symptoms can be improved by administering the composition of the present invention.
본 명세서에서 '아토피 피부염'이란 아토피성의 피부염, 피부질환, 건선, 습진, 가려움증 등을 모두 포함하는 넓은 의미로 사용된다.In the present specification, 'atopic dermatitis' is used in a broad sense including atopic dermatitis, skin disease, psoriasis, eczema, itching, and the like.
본 명세서에서, '약재'란 생약 또는 한약재를 의미하는 것으로서, 약용으로 사용하기 위해 자연에서 채취할 수 있는 모든 초(草)·목(木)·곡(穀) 등을 포괄한다.In the present specification, 'medicine' refers to herbal medicine or herbal medicine, and includes all herbs, trees, grains, etc. that can be harvested from nature for medicinal use.
본 발명의 조성물은 열수 추출물, 가온 추출물, 액상 추출물, 농축 액상 추출물, 동결건조 분말 및 분무건조 분말로 이루어진 군에서 선택되는 하나 이상의 제형으로 구성될 수 있다. 구체적으로, 본 발명의 조성물은 경피 흡수제(외용피부연고제), 물비누, 비누, 에센스, 젤, 액체세정료, 로션, 폼, 유연수, 화장수, 클렌징폼, 클렌징로션, 클렌징크림, 팩, 맛사지 크림, 에몰리언트(emollient)크림, 에몰리언트(emollient)로션, 화장수에센스, 수렴화장수(astringent), 수용성 리퀴드, 파운데이션, 메이크업베이스, 바디용로션, 수렴화장수, 유연화장수, 영양 화장수, 트리트먼트, 스킨로션, 밀크로션, 영양로션, 영양에센스, 수중유(O/W)형 및 유중수(W/O)형으로 이루어진 군에서 선택되는 하나 이상의 제형일 수 있다. 예시적인 실시예에서, 본 발명의 조성물은 화장품으로 허용되는 유화제, 각종 오일 성분(지방, 오일, 에스테르, 실리콘 오일 등), 농후제, 방부제, 향유, 킬레이트화제, 물과 같은 통상적인 담체를 더 포함할 수 있다.The composition of the present invention may be composed of one or more formulations selected from the group consisting of a hot water extract, a warm extract, a liquid extract, a concentrated liquid extract, a freeze-dried powder, and a spray-dried powder. Specifically, the composition of the present invention is a transdermal absorbent (external skin ointment), water soap, soap, essence, gel, liquid cleanser, lotion, foam, softening water, lotion, cleansing foam, cleansing lotion, cleansing cream, pack, massage cream, emollient cream, emollient lotion, lotion essence, astringent lotion, water-soluble liquid, foundation, makeup base, body lotion, astringent lotion, softening lotion, nourishing lotion, treatment, skin lotion, milk lotion , It may be one or more formulations selected from the group consisting of nutrient lotion, nutrient essence, oil-in-water (O/W) type and water-in-oil (W/O) type. In an exemplary embodiment, the composition of the present invention further contains conventional carriers such as cosmetically acceptable emulsifiers, various oil components (fat, oil, ester, silicone oil, etc.), thickeners, preservatives, fragrance oils, chelating agents, and water. can include
본 발명의 조성물은 상기 제형 전체 조성에 대하여 0.005-95 wt%로 포함될 수 있다.The composition of the present invention may be included in 0.005-95 wt% based on the total composition of the formulation.
본 명세서에서, '지표성분으로 포함'하는 조성물이란 해당 성분이 지표성분으로 함유된 생약 또는 한약재를 포함하는 조성물을 의미할 수 있고, 이때 상기 생약 또는 한약재란 생약 또는 한약재를 물리적, 화학적 또는 생물학적 공정을 거쳐 얻은 것도 포함한다.In the present specification, a composition 'included as a marker ingredient' may mean a composition containing a herbal medicine or herbal medicine containing the corresponding ingredient as a marker ingredient, and in this case, the herbal medicine or herbal medicine is a physical, chemical, or biological process Including those obtained through
이하, 본 발명의 실시예들을 제조예와 실험예를 통해 상세하게 설명하나, 본 발명의 효과가 하기 실험예에 의해 제한되지 아니함은 자명하다.Hereinafter, embodiments of the present invention will be described in detail through preparation examples and experimental examples, but it is obvious that the effects of the present invention are not limited by the following experimental examples.
제조예: 본 발명의 조성물의 제조Preparation Example: Preparation of the composition of the present invention
실시예 1Example 1
백반 40 g, 백선피 40 g, 고삼 40 g, 토복령 40 g 및 황백 40 g의 생약재 원료들을 정제수로 충분히 세척한 후 혼합하였다. 정제수 20 L를 채운 열탕 증류기에 생약재 원료들을 투입하고 약 80-100 ℃로 30시간 동안 가열하여 열수 추출물을 얻었다. 추출에 사용된 생약재들은 여과하여 제거하고, 열수 추출물을 약 90-100 ℃로 가열하면서 약 4-10 ℃의 냉각수관을 이용하여 증류액을 획득하였다. 증류액을 12,000 rpm 및 4 ℃에서 30분간 원심분리하여 고형분을 제거하고 상등액을 취하여 조성물을 제조하였다.Herbal raw materials of 40 g of alum, 40 g of white sandpiper, 40 g of high ginseng, 40 g of Tobokryeong, and 40 g of yellow white were thoroughly washed with purified water and then mixed. Herbal raw materials were put into a hot water distiller filled with 20 L of purified water and heated at about 80-100 ° C for 30 hours to obtain a hot water extract. The herbal medicines used for extraction were removed by filtration, and a distillate was obtained using a cooling water pipe at about 4-10 °C while heating the hot water extract at about 90-100 °C. The distillate was centrifuged at 12,000 rpm and 4 °C for 30 minutes to remove the solid content, and the supernatant was taken to prepare a composition.
실시예 2Example 2
백반 40 g, 백선피 40 g, 고삼 40 g, 토복령 40 g 및 황백 40 g의 생약재 원료들을 정제수로 충분히 세척한 후 혼합하고 에탄올(95 w/w%)을 이용하여 3시간 동안 70 ℃로 가온 추출하여 조성물을 제조하였다.Herbal raw materials of 40 g of alum, 40 g of white ginseng husk, 40 g of gosam, 40 g of earthen cormorant, and 40 g of hwangbaek were thoroughly washed with purified water, mixed, and heated at 70 ° C for 3 hours using ethanol (95 w/w%). The composition was prepared by hot extraction.
실시예 3Example 3
백반 50 g, 백선피 50 g, 고삼 50 g 및 토복령 50 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 50 g of alum, 50 g of white ginseng skin, 50 g of high ginseng, and 50 g of Tobokryeong in the same manner as in Example 2.
비교예 1Comparative Example 1
백반 100 g, 백선피 100 g, 고삼 10 g 및 토복령 10 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 100 g of alum, 100 g of white ginseng skin, 10 g of Gosam, and 10 g of Tobokryeong in the same manner as in Example 2.
비교예 2Comparative Example 2
백반 10 g, 백선피 10 g, 고삼 100 g, 토복령 10 g 및 황백 100 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 10 g of white rice, 10 g of white rice skin, 100 g of high ginseng, 10 g of Tobokryeong, and 100 g of yellow white in the same manner as in Example 2.
비교예 3Comparative Example 3
백반 200 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 200 g of alum in the same manner as in Example 2.
비교예 4Comparative Example 4
백선피 200 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 200 g of ringworm skin in the same manner as in Example 2.
비교예 5Comparative Example 5
고삼 200 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 200 g of high ginseng in the same manner as in Example 2.
비교예 6Comparative Example 6
토복령 200 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 200 g of Tobokryeong in the same manner as in Example 2.
비교예 7Comparative Example 7
황백 200 g을 상기 실시예 2와 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 200 g of yellow white in the same manner as in Example 2.
실시예 1-1Example 1-1
백반, 백선피, 고삼, 토복령 및 황백의 생약재 원료들을 정제수로 충분히 세척한 후, 각 원료를 정제수 20 L를 채운 열탕 증류기에 별개로 투입하고 약 80-100 ℃로 30시간 동안 가열하여 각각의 열수 추출물을 얻었다. 추출에 사용된 생약재들은 여과하여 제거하고, 각 열수 추출물을 약 90-100 ℃로 가열하면서 약 4-10 ℃의 냉각수관을 이용하여 각각의 증류액을 획득하였다. 각 증류액을 12,000 rpm 및 4 ℃에서 30분간 원심분리하여 고형분을 제거하고 각각의 상등액을 취하였다. 백반 상등액 0.4 L, 백선피 상등액 0.4 L, 고삼 상등액 0.4 L, 토복령 상등액 0.4 L 및 황백 상등액 0.4 L을 서로 혼합하여 조성물을 제조하였다.After thoroughly washing the herbal medicine raw materials of alum, white sandpiper, red ginseng, tobokryeong, and hwangbaek with purified water, each raw material is separately put into a hot water distiller filled with 20 L of purified water and heated at about 80-100 ° C for 30 hours. A hot water extract was obtained. The herbal medicines used for extraction were removed by filtration, and each distillate was obtained using a cooling water pipe at about 4-10 °C while heating each hot water extract at about 90-100 °C. Each distillate was centrifuged at 12,000 rpm and 4 °C for 30 minutes to remove the solid content, and each supernatant was taken. A composition was prepared by mixing 0.4 L of alum supernatant, 0.4 L of ringworm supernatant, 0.4 L of high ginseng supernatant, 0.4 L of Tobokryeong supernatant, and 0.4 L of yellow-white supernatant.
실시예 1-2Example 1-2
백반 40 g, 백선피 40 g, 고삼 40 g 및 황백 40 g을 상기 실시예 1과 동일한 방법으로 추출하여 조성물을 제조하였다.A composition was prepared by extracting 40 g of white rice, 40 g of white rice skin, 40 g of gosam, and 40 g of yellow white in the same manner as in Example 1.
실험예 1: 각질형성세포에 대한 독성 평가Experimental Example 1: Evaluation of toxicity to keratinocytes
본 발명의 조성물의 각질형성세포에 대한 독성을 다음과 같이 시험하였다.The toxicity of the composition of the present invention to keratinocytes was tested as follows.
96-well plate를 사용하여 1% FBS(Fetal bovine serum)를 포함하는 DMEM(Dulbecco's modified Eagle's medium) 배지에 인간 각질형성세포(human keratinocyte cell line, HaCaT)를 접종하여 배양하였다. 세포가 배양 접시에 60% 정도 차면 세럼이 들어있지 않은 배지로 바꾸어 16-24시간 배양한 후에 상기 실시예의 조성물을 포함한 배지로 교환해주었다. 48시간 뒤에 MTT(Tetrazolium-based colorimetric) 용액을 10%로 함유한 배지로 교환해주었다. 2-4시간 동안 배양한 뒤 배지를 제거하고 DMSO(Dimethyl sulfoxide)로 배양접시 밑에 남아있는 침전물을 녹여주었다. ELISA leader로 570 nm에서의 흡광도를 측정하고 평균값을 산출하였으며, 그 결과는 도 1과 같았다. 도 1 내지 3에서 C, C1, C2 및 C3는 각각 대조군 및 실시예 1 내지 3의 조성물을 의미한다.Using a 96-well plate, human keratinocyte cell line (HaCaT) was inoculated and cultured in DMEM (Dulbecco's modified Eagle's medium) medium containing 1% FBS (Fetal bovine serum). When the cells were filled to about 60% in the culture dish, the culture medium was changed to a serum-free medium and cultured for 16-24 hours, and then the medium was replaced with the medium containing the composition of the above example. After 48 hours, the medium was replaced with a medium containing 10% MTT (Tetrazolium-based colorimetric) solution. After culturing for 2-4 hours, the medium was removed and the precipitate remaining at the bottom of the culture dish was dissolved with DMSO (Dimethyl sulfoxide). The absorbance at 570 nm was measured with an ELISA leader and the average value was calculated, and the result was the same as in FIG. 1. In Figures 1 to 3, C, C1, C2 and C3 denote the control group and the compositions of Examples 1 to 3, respectively.
도 1에 나타난 바와 같이, 본 발명의 조성물은 각질형성세포에 대한 독성을 나타내지 않음을 알 수 있다.As shown in Figure 1, it can be seen that the composition of the present invention does not exhibit toxicity to keratinocytes.
실험예 2: 항산화 활성 평가Experimental Example 2: Evaluation of antioxidant activity
본 발명의 조성물의 항산화 활성을 평가하기 위해 다음과 같이 산화질소(NO)의 소거능을 시험하였다.In order to evaluate the antioxidant activity of the composition of the present invention, nitric oxide (NO) scavenging ability was tested as follows.
10% FBS(fetal bovine serum)과 100 unit/ml의 페니실린 및 스트렙토마이신이 첨가된 DMEM(Dulbecco's modified Eagle's medium) 배지에 Raw 264.7 대식세포를 1×106 cell/ml의 농도로 96-well plate에 접종하고, 37 ℃, 5% CO2에서 하룻밤 동안 배양하였다. 다음날 배지를 제거하고 새로운 배지로 교환한 후, 상기 실시예 및 비교예의 조성물을 50 μl씩 세포에 처리하였다. 30분간 CO2 인큐베이터에서 배양 후 50 μl(1 μg/ml)의 LPS(lipopolysaccharide)를 함유한 배지를 처리하고 인큐베이터(5% CO2, 37 ℃)에서 24시간 동안 배양하였다. 대조군으로서 PBS(phosphate buffered saline)를 사용하였다. Griess reagent I (NED solution)과 Griess reagent II (Sulfaniliamide solution)을 동량으로 혼합하여 넣은 후, 10분간 반응시킨 다음 microplate reader로 540 nm에서의 광밀도(optical density)를 측정하였다. 산화질소(NO)의 농도는 아질산나트륨 (Sodium Nitrate)의 표준곡선(0-100 μM)을 이용하여 계산하였다. 측정 결과는 하기 표 1과 같았다.Raw 264.7 macrophages in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS (fetal bovine serum) and 100 units/ml of penicillin and streptomycin were plated in a 96-well plate at a concentration of 1×10 6 cell/ml. Inoculated and incubated overnight at 37 °C, 5% CO 2 . The next day, after removing the medium and replacing it with a fresh medium, 50 μl of each of the compositions of Examples and Comparative Examples was applied to the cells. After culturing in a CO 2 incubator for 30 minutes, 50 μl (1 μg/ml) of LPS (lipopolysaccharide) was treated with a culture medium and cultured in an incubator (5% CO 2 , 37 °C) for 24 hours. Phosphate buffered saline (PBS) was used as a control. Griess reagent I (NED solution) and Griess reagent II (Sulfaniliamide solution) were mixed in equal amounts, reacted for 10 minutes, and then optical density at 540 nm was measured using a microplate reader. The concentration of nitric oxide (NO) was calculated using a standard curve (0-100 μM) of sodium nitrite. The measurement results were shown in Table 1 below.
상기 표 1에 나타난 바와 같이, 본 발명의 조성물들은 LPS에 의해 촉진된 NO의 생성량을 40-50% 이상 감소시켰기 때문에 우수한 항산화 및 항염 활성이 있음을 알 수 있다. 또한, 추출방법, 조성 또는 배합비율에 따라 활성에 차이가 있으며, 각 원료들의 단일 추출물 대비 상승작용 효과(synergistic effect)를 나타냄을 알 수 있다.As shown in Table 1, it can be seen that the compositions of the present invention have excellent antioxidant and anti-inflammatory activities because they reduced the production of NO stimulated by LPS by 40-50% or more. In addition, it can be seen that there is a difference in activity according to the extraction method, composition or mixing ratio, and that each raw material exhibits a synergistic effect compared to a single extract.
실험예 3: 염증성 사이토카인 생성억제 활성 평가Experimental Example 3: Evaluation of inflammatory cytokine production inhibitory activity
본 발명의 조성물의 항염 활성을 다음과 같은 방법으로 측정하였다. 상기 실험예 2와 같이 배양한 RAW 264.7 세포에 상기 실시예 및 비교예의 조성물을 먼저 처리한 다음 LPS(lipopolysaccharide)를 1 μg/ml 농도로 처리하여 24시간 배양한 후, 상층액을 회수하여 ELISA 키트로 IL-8(interleukin-8)을 측정하였다. Avidin이 결합된 검출용 항체를 사용하여 반응시킨 후 microplate reader로 450 nm에서 흡광도를 측정하였으며, 대조군으로서 PBS(phosphate buffered saline)를 사용하였다.The anti-inflammatory activity of the composition of the present invention was measured by the following method. RAW 264.7 cells cultured as in Experimental Example 2 were first treated with the compositions of Examples and Comparative Examples, then treated with LPS (lipopolysaccharide) at a concentration of 1 μg/ml, cultured for 24 hours, and the supernatant was recovered to obtain an ELISA kit. IL-8 (interleukin-8) was measured. After reaction using an avidin-coupled detection antibody, absorbance was measured at 450 nm with a microplate reader, and phosphate buffered saline (PBS) was used as a control.
또한, TNF-α 발현을 분석하기 위하여 웨스턴블랏 분석(Western blot analysis)을 수행하였다. 상기 실시예 및 비교예의 조성물이 처리된 배지에서 자란 세포들을 PBS로 씻어내고 0.05% 트립신-EDTA를 처리한 후 원심분리하여 세포를 취한 다음 lysis buffer로 용해한 후, 세포 내 잔사물을 분리시키고 동량의 단백질을 SDS-폴리아크릴아마이드 겔 전기영동(SDS-Polyacrylamide gel elecrophoresis)으로 분리하였다. 분리된 단백질을 니트로섬유소막(nitrocellulose membrane)으로 전이시킨 후, 항체와 2차항체 반응을 실시하고 ECL(enhanced chemiluminoesence) 용액을 처리한 다음 X-ray 필름에 감광시켜 단백질의 발현 정도를 분석하였다.In addition, Western blot analysis was performed to analyze TNF-α expression. Cells grown in the medium treated with the compositions of Examples and Comparative Examples were washed with PBS, treated with 0.05% trypsin-EDTA, centrifuged to collect cells, lysed with lysis buffer, and intracellular debris was separated and the same amount Proteins were separated by SDS-Polyacrylamide gel elecrophoresis. After transferring the separated protein to a nitrocellulose membrane, antibody and secondary antibody reaction were performed, ECL (enhanced chemiluminoesence) solution was treated, and the protein expression level was analyzed by exposure to X-ray film.
IL-8의 분비량과 TNF-α의 발현량은 하기 표 2와 같았다.The secretion of IL-8 and the expression of TNF-α were shown in Table 2 below.
상기 표 2에 나타난 바와 같이 본 발명의 조성물들은 LPS에 의해 촉진된 염증성 사이토카인인 IL-8과 TNF-α의 생성량을 50-60% 이상 감소시켰기 때문에 우수한 항염 활성이 있음을 알 수 있다. 또한, 추출방법, 조성 또는 배합비율에 따라 활성에 차이가 있으며, 각 원료들의 단일 추출물 대비 상승작용 효과를 나타냄을 알 수 있다.As shown in Table 2, it can be seen that the compositions of the present invention have excellent anti-inflammatory activity because they reduced the production of IL-8 and TNF-α, which are inflammatory cytokines promoted by LPS, by 50-60% or more. In addition, it can be seen that there is a difference in activity depending on the extraction method, composition or mixing ratio, and that each raw material exhibits a synergistic effect compared to a single extract.
실험예 4: 아토피 피부염 개선효능 관능평가Experimental Example 4: Sensory evaluation of atopic dermatitis improving efficacy
본 발명의 조성물로 제조된 화장품의 아토피 피부염에 대한 개선효능을 평가하기 위하여, 아토피 피부염을 가진 5-10세 어린이 10명을 대상으로 관능평가를 수행하였다. 상기 실시예 1의 조성물을 공지된 통상적인 부형제(유화제, 분산제, 보존제)와 혼합하여 제조한 로션을 아토피 피부염이 발병한 부위에 1일 2회, 0.5~1 g/회 정도 펴발라 주었다. 평가는 1개월 사용 후 5점 만점 만족척도로 평가하도록 하고, 그 평균값은 하기 표 3과 같았다.In order to evaluate the improvement effect of the cosmetics prepared from the composition of the present invention on atopic dermatitis, sensory evaluation was performed on 10 children aged 5-10 years with atopic dermatitis. A lotion prepared by mixing the composition of Example 1 with known conventional excipients (emulsifier, dispersant, preservative) was spread on the atopic dermatitis affected area twice a day, 0.5 to 1 g/time. The evaluation was evaluated on a 5-point satisfaction scale after 1 month of use, and the average value was shown in Table 3 below.
상기 표 3에 나타난 바와 같이 본 발명의 조성물들은 아토피 피부염과 같은 중증 피부질환에 우수한 개선효과를 나타냄을 알 수 있다.As shown in Table 3, it can be seen that the compositions of the present invention exhibit excellent improvement effects on severe skin diseases such as atopic dermatitis.
이상에서 본 발명의 실시예를 중심으로 설명하였으나 이는 단지 예시일 뿐 본 발명을 한정하는 것이 아니며, 본 발명이 속하는 분야에서 통상의 지식을 가진 자라면 본 발명의 실시예의 본질적인 특성을 벗어나지 않는 범위에서 이상에 예시되지 않은 여러 가지의 변형과 응용이 가능함을 알 수 있을 것이다. 예를 들어, 본 발명의 실시예에 구체적으로 나타난 각 구성 요소는 변형하여 실시할 수 있다. 그리고 이러한 변형과 응용에 관계된 차이점들은 첨부된 청구 범위에서 규정하는 본 발명의 범위에 포함되는 것으로 해석되어야 할 것이다.Although the above has been described with reference to the embodiments of the present invention, this is only an example and does not limit the present invention, and those skilled in the art to which the present invention belongs will be able to It will be appreciated that various modifications and applications not exemplified above are possible. For example, each component specifically shown in the embodiment of the present invention can be modified and implemented. And differences related to these modifications and applications should be construed as being included in the scope of the present invention as defined in the appended claims.
Claims (12)
아토피 피부염의 개선 또는 치료용 조성물.A distillate of a hot water extract of a mixture containing 2-8 parts by weight of alum, 2-8 parts by weight of baekseonpi, 2-8 parts by weight of high ginseng, 2-8 parts by weight of Tobokryeong and 2-8 parts by weight of yellow buckwheat
A composition for improving or treating atopic dermatitis.
상기 혼합물은,
황산알루미늄칼륨수화물, 딕탐닌, 마트린, 망기페린 및 에피카테킨으로 이루어진 군에서 선택되는 하나 이상의 지표성분을 포함하는 것을 특징으로 하는
아토피 피부염의 개선 또는 치료용 조성물.According to claim 1,
The mixture is
Characterized in that it contains at least one indicator component selected from the group consisting of aluminum sulfate potassium hydrate, dictamnin, matrine, mangiferin and epicatechin
A composition for improving or treating atopic dermatitis.
아토피 피부염의 개선 또는 치료용 조성물.2-8 parts by weight of a distillate of alum hot water extract, 2-8 parts by weight of a distillate of a hot water extract of Baekseonpi, 2-8 parts by weight of a distillate of a hot water extract of Gosam, 2-8 parts by weight of a distillate of a hot water extract of Tobokryeong, and containing 2-8 parts by weight of distillate of yellow-white hot water extract
A composition for improving or treating atopic dermatitis.
(b) 상기 열수 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계; 및
(c) 상기 액화된 것을 원심분리하여 고형분을 제거하고 상등액을 취하여 증류액을 수득하는 단계를 포함하는
아토피 피부염의 개선 또는 치료용 조성물의 제조 방법.(a) A mixture containing 2-8 parts by weight of alum, 2-8 parts by weight of baekseon hull, 2-8 parts by weight of high ginseng, 2-8 parts by weight of earthen buckwheat, and 2-8 parts by weight of yellow white is heated to 80-100 ° C for 8-8 parts by weight. heating for 48 hours and filtering to obtain a hot water extract;
(b) liquefying the steam generated by heating the hot water extract at 90-100 °C with a cooling water pipe at 4-10 °C; and
(c) centrifuging the liquefied material to remove solids and taking the supernatant to obtain a distillate;
A method for preparing a composition for improving or treating atopic dermatitis.
(b) 상기 각 열수 추출물을 90-100 ℃로 가열하여 생성된 증기를 4-10 ℃의 냉각수관으로 액화시키는 단계;
(c) 상기 액화된 것을 8,000-14,000 rpm 및 2-8 ℃에서 10-50분간 원심분리하여 고형분을 제거하고 상등액을 취하여 각각의 증류액을 수득하는 단계; 및
(d) 상기 백반의 증류액 2-8 중량부, 백선피의 증류액 2-8 중량부, 고삼의 증류액 2-8 중량부, 토복령의 증류액 2-8 중량부 및 황백의 증류액 2-8 중량부를 서로 혼합하는 단계를 포함하는
아토피 피부염의 개선 또는 치료용 조성물의 제조 방법.(a) heating and filtering alum, baekseonpi, gosam, tobokryeong, and yellow baek at 80-100 ° C. for 8-48 hours, respectively, to obtain respective hot-water extracts;
(b) liquefying the steam generated by heating each of the hot water extracts at 90-100 ° C with a cooling water pipe at 4-10 ° C;
(c) centrifuging the liquefied product at 8,000-14,000 rpm and 2-8 ° C. for 10-50 minutes to remove the solid content and taking the supernatant to obtain each distillate; and
(d) 2-8 parts by weight of the distillate of the alum, 2-8 parts by weight of the distillate of baekseonpi, 2-8 parts by weight of the distillate of gosam, 2-8 parts by weight of the distillate of tobokryeong, and 2-8 parts by weight of the distillate of yellow white -including mixing 8 parts by weight with each other
A method for preparing a composition for improving or treating atopic dermatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220069647A KR102537948B1 (en) | 2022-06-08 | 2022-06-08 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220069647A KR102537948B1 (en) | 2022-06-08 | 2022-06-08 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102537948B1 true KR102537948B1 (en) | 2023-05-30 |
Family
ID=86529734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220069647A KR102537948B1 (en) | 2022-06-08 | 2022-06-08 | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102537948B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150088154A (en) * | 2014-01-23 | 2015-07-31 | 주식회사 리오엘리 | Composition comprising extracts of sophora flavescens, glycyrrhiza uralensis fischer and dictamnus dasycarpus turcz for preventing and treating atopic dermatitis and method of preparering the same |
| KR101799516B1 (en) * | 2017-05-04 | 2017-11-20 | 이종열 | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same |
-
2022
- 2022-06-08 KR KR1020220069647A patent/KR102537948B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150088154A (en) * | 2014-01-23 | 2015-07-31 | 주식회사 리오엘리 | Composition comprising extracts of sophora flavescens, glycyrrhiza uralensis fischer and dictamnus dasycarpus turcz for preventing and treating atopic dermatitis and method of preparering the same |
| KR101799516B1 (en) * | 2017-05-04 | 2017-11-20 | 이종열 | Skin external composition for improving atopic dermatitis and cosmetic composotion including the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100772575B1 (en) | External composition for improvement of skin containing herbal extracts | |
| KR101205097B1 (en) | Preparation method of aloe fermentation and hydrolysis extract showing prevention and improvement effect of atopic dermatitis and cosmetics prepared using the same | |
| KR20050046810A (en) | Chinese herbs extract | |
| KR101782268B1 (en) | A composition for treating atopic dermatitis comprising the extract of herbal mixture | |
| KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR101270736B1 (en) | A composition comprising extract from herbal for improving pruritus | |
| KR101973950B1 (en) | Composition comprising mixture of a citrus unshiu peel extract and chamaecyparis obtuse extract for alleviating skin inflammation or skin hyperpigmentation by yellow sand or fine dust | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102537948B1 (en) | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof | |
| KR102537982B1 (en) | Composition for improvement or treatment of severe dermatopathy containing biochemical mineral recombinant complex ingredients and preparing method thereof | |
| KR20050014947A (en) | Cosmetic Composition for Improving Atopic Dermatitis Containing Extracts from Plants as Active Ingredient | |
| KR101705354B1 (en) | A composition comprising the alcohol extract of Botrychium ternatum for preventing or treating skin inflammation | |
| KR102490086B1 (en) | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof | |
| CN115429725B (en) | Cosmetic composition for antioxidation, anti-inflammatory and skin tranquilization | |
| KR100670850B1 (en) | Composition containing Gentianae Macrophyllae Radix Extract for treatment hypersensitive skin disease | |
| KR102585932B1 (en) | Composition for improvement or treatment of atopic dermatitis containing natural complex components and preparing method thereof | |
| KR102514502B1 (en) | Composition for Improving for Atopic Dermatitis, Pruritis, and Inflammation Comprising Sparasis crispa, vegetable worms, and Tuber melanosporum as Active Ingredient | |
| CN117100801A (en) | Medicinal composition for resisting atopic dermatitis, and preparation method and application thereof | |
| WO2022010024A1 (en) | Herbal composition for alleviating or treating atopic dermatitis, comprising natural composite ingredients, and method for preparing same | |
| KR101698869B1 (en) | A composition for treatment of Atopic dermatitis containing oriental medicine herbs | |
| KR102144566B1 (en) | A composition for preventing or terating atopic dermatitis comprising lycopi herba extract as an active ingredient | |
| KR20220132478A (en) | Composition for improvement or treatment of atopic dermatitis containing index components of crude drugs and preparing method thereof | |
| KR102120758B1 (en) | Composition for preventing, ameliorating or treating allergic disease comprising coffee extract as effective component | |
| KR101599458B1 (en) | A composition comprising the alcohol extract of Korthalsella japonica(Thunb.) Engl for preventing or treating skin inflammation | |
| KR20120023507A (en) | Composition for treating atopic dermatitis comprising extract from colored potatoes as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| GRNT | Written decision to grant |